Teva Women's Health Announces New Data on Phase III Investigational Progesterone Vaginal Ring
Teva Women's Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), today announced findings from a Phase III clinical trial of Milprosa^TM (progesterone), an investigational weekly progesterone vaginal ring for luteal supplementation in women undergoing in vitro fertilization (IVF). These data were presented as an oral presentation at the 68^th Annual Meeting of the American Society for Reproductive Medicine (ASRM).
Data from a randomized, single-blind trial assessing the pregnancy rate of Milprosa™ versus daily 8 percent progesterone gel for luteal supplementation in women undergoing embryo transfer during IVF at days three and five were presented. Results showed clinical pregnancy rates for Milprosa™ were similar to progesterone gel, regardless of the day the embryos were returned to the uterus. Researchers concluded that Milprosa™ is effective in luteal supplementation in IVF and that clinical pregnancy rates were similar for the vaginal ring and 8 percent progesterone gel.^1
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.